Introduction: Retroperitoneal sarcoma (RPS) is a rare disease accounting for 0.1%-0.2% of all malignancies. Management of RPS is complex and requires multidisciplinary, tailored treatment strategies at all stages, but especially in the context of metastatic or multifocal recurrent disease. Due to the rarity and heterogeneity of this family of diseases, the literature to guide management is limited. Methods: The Trans-Atlantic Retroperitoneal Sarcoma Working Group (TARPSWG) is an international collaboration of sarcoma experts from all disciplines convened in an effort to overcome these limitations. The TARPSWG has compiled the available evidence surrounding metastatic and multifocally recurrent RPS along with expert opinion in an iterative process to generate a consensus document regarding the complex management of this disease. The objective of this document is to guide sarcoma specialists from all disciplines in the diagnosis and treatment of multifocal recurrent or metastatic RPS. Results: All aspects of patient assessment, diagnostic processes, local and systemic treatments, and palliation are reviewed in this document, and consensus recommendations provided accordingly. Recommendations were guided by available evidence, in conjunction with expert opinion where evidence was lacking. Conclusions: This consensus document combines the available literature regarding the management of multifocally recurrent or metastastic RPS with the practical expertise of high-volume sarcoma centers from multiple countries. It is designed as a tool for decision making in the complex multidisciplinary management of this condition and is expected to standardize management across centers, thereby ensuring that patients receive the highest quality care.
Introduction: Retroperitoneal sarcoma (RPS) is a rare disease accounting for 0.1%-0.2% of all malignancies. Management of RPS is complex and requires multidisciplinary, tailored treatment strategies at all stages, but especially in the context of metastatic or multifocal recurrent disease. Due to the rarity and heterogeneity of this family of diseases, the literature to guide management is limited. Methods: The Trans-Atlantic Retroperitoneal Sarcoma Working Group (TARPSWG) is an international collaboration of sarcoma experts from all disciplines convened in an effort to overcome these limitations. The TARPSWG has compiled the available evidence surrounding metastatic and multifocally recurrent RPS along with expert opinion in an iterative process to generate a consensus document regarding the complex management of this disease. The objective of this document is to guide sarcoma specialists from all disciplines in the diagnosis and treatment of multifocal recurrent or metastatic RPS. Results: All aspects of patient assessment, diagnostic processes, local and systemic treatments, and palliation are reviewed in this document, and consensus recommendations provided accordingly. Recommendations were guided by available evidence, in conjunction with expert opinion where evidence was lacking. Conclusions: This consensus document combines the available literature regarding the management of multifocally recurrent or metastastic RPS with the practical expertise of high-volume sarcoma centers from multiple countries. It is designed as a tool for decision making in the complex multidisciplinary management of this condition and is expected to standardize management across centers, thereby ensuring that patients receive the highest quality care.
Authors: Melissa C Brouwers; Michelle E Kho; George P Browman; Jako S Burgers; Francoise Cluzeau; Gene Feder; Béatrice Fervers; Ian D Graham; Jeremy Grimshaw; Steven E Hanna; Peter Littlejohns; Julie Makarski; Louise Zitzelsberger Journal: CMAJ Date: 2010-07-05 Impact factor: 8.262
Authors: O S Nielsen; I Judson; Q van Hoesel; A le Cesne; H J Keizer; J Y Blay; A van Oosterom; J A Radford; L Svancárová; K Krzemienlecki; C Hermans; M van Glabbeke; J W Oosterhuis; J Verweij Journal: Eur J Cancer Date: 2000-01 Impact factor: 9.162
Authors: Samuel Kim; Harald C Ott; Cameron D Wright; John C Wain; Christopher Morse; Henning A Gaissert; Dean M Donahue; Douglas J Mathisen; Michael Lanuti Journal: Ann Thorac Surg Date: 2011-10-31 Impact factor: 4.330
Authors: S Schur; K Hoetzenecker; W Lamm; W J Koestler; G Lang; G Amann; P Funovics; E Nemecek; I Noebauer; R Windhager; W Klepetko; T Brodowicz Journal: Eur J Cancer Date: 2014-07-02 Impact factor: 9.162
Authors: Andrew J Wagner; Izabela Malinowska-Kolodziej; Jeffrey A Morgan; Wei Qin; Christopher D M Fletcher; Natalie Vena; Azra H Ligon; Cristina R Antonescu; Nikhil H Ramaiya; George D Demetri; David J Kwiatkowski; Robert G Maki Journal: J Clin Oncol Date: 2010-01-04 Impact factor: 44.544
Authors: Carol J Swallow; Dirk C Strauss; Sylvie Bonvalot; Piotr Rutkowski; Anant Desai; Rebecca A Gladdy; Ricardo Gonzalez; David E Gyorki; Mark Fairweather; Winan J van Houdt; Eberhard Stoeckle; Jae Berm Park; Markus Albertsmeier; Carolyn Nessim; Kenneth Cardona; Marco Fiore; Andrew Hayes; Dimitri Tzanis; Jacek Skoczylas; Samuel J Ford; Deanna Ng; John E Mullinax; Hayden Snow; Rick L Haas; Dario Callegaro; Myles J Smith; Toufik Bouhadiba; Silvia Stacchiotti; Robin L Jones; Thomas DeLaney; Christina L Roland; Chandrajit P Raut; Alessandro Gronchi Journal: Ann Surg Oncol Date: 2021-04-14 Impact factor: 4.339
Authors: Michele M Gage; Neeraja Nagarajan; Jessica M Ruck; Joseph K Canner; Salma Khan; Katherine Giuliano; Faiz Gani; Christopher Wolfgang; Fabian M Johnston; Nita Ahuja Journal: Oncotarget Date: 2019-03-29
Authors: Randall J Brenneman; Nima Sharifai; Benjamin Fischer-Valuck; Comron Hassanzadeh; Jeffrey Guzelian; John S A Chrisinger; Jeff M Michalski; Peter Oppelt; Brian C Baumann Journal: Front Oncol Date: 2019-09-26 Impact factor: 6.244
Authors: Gustavo R Sarria; Vera Petrova; Frederik Wenz; Yasser Abo-Madyan; Elena Sperk; Frank A Giordano Journal: Radiat Oncol Date: 2020-05-14 Impact factor: 3.481